Canine pancreatitis injectable lands U.S. distributionMay 18, 2023Panoquell-CA1’s active ingredient, fuzapladib sodium, has been approved for canine use in Japan since 2018.
SPONSORED CONTENTCurrent users report reduced stress for parvovirus care1Research shows that our Canine Parvovirus Monoclonal Antibody can help veterinary care teams work with less stress.1 Learn what CPMA can do for your parvo protocol. + Read More
Canine pancreatitis injectable OKed by FDANovember 21, 2022Panoquell-CA1 has been granted conditional approval from the U.S. Food and Drug Administration (FDA) for the management of clinical signs associated with acute onset of pancreatitis in canines.
Clinical trial aims to treat canine pancreatitisFebruary 6, 2020ISK and AlcheraBio are seeking clinics to serve as clinical investigator sites to explore treatment options for patients diagnosed with acute canine pancreatitis (ACP).